These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11552628)

  • 1. [Therapeutic action and efficiency of fevarin (fluvoxamine) in patients with non-psychotic anxious and apathic-adynamic depressions].
    Neznamov GG; Siuniakov SA; Teleshova ES; Dorofeeva OA; Chumakov DB; Davydova IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(8):19-24. PubMed ID: 11552628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Selective serotonin reuptake inhibitors in the therapy of various types of endogenous depressions].
    Panteleeva GP; Abramova LI; Korenev AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(3):36-41. PubMed ID: 10758646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fluvoxamine (fevarin) in the treatment of depression].
    Sheĭfer MS; Tsybina MI; Davydenko MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):64-7. PubMed ID: 11195542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fluvoxamine (fevarin) in psychogenic depression].
    Dubnitskaia EB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(12):48-50. PubMed ID: 11811127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
    J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fluvoxamine in the treatment of anxiety-depressive spectrum disorders].
    Medvedev VE; Kardashian RA; Frolova VI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(6):101-109. PubMed ID: 39072574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sertraline in child and adolescent psychiatry].
    Voloshina VM; Kashnikova AA; Tatarova IN; Kim LV; Koren' EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(8):25-8. PubMed ID: 11552629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anxious depression and response to treatment.
    Nelson JC
    Am J Psychiatry; 2008 Mar; 165(3):297-9. PubMed ID: 18316424
    [No Abstract]   [Full Text] [Related]  

  • 9. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
    Houck C
    Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychiatric comorbidities and use of milnacipran in patients with chronic dizziness.
    Horii A; Imai T; Kitahara T; Uno A; Morita Y; Takahashi K; Inohara H
    J Vestib Res; 2016 Jul; 26(3):335-40. PubMed ID: 27392838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anxiety and depression in the elderly: implications for diagnosis and treatment.
    Dunner DL
    CNS Spectr; 2003 Dec; 8(12 Suppl 3):5. PubMed ID: 14978457
    [No Abstract]   [Full Text] [Related]  

  • 12. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.
    Zanardi R; Franchini L; Serretti A; Perez J; Smeraldi E
    J Clin Psychiatry; 2000 Jan; 61(1):26-9. PubMed ID: 10695642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SSRIs in anxious-agitated depression: a post-hoc analysis of 279 patients.
    Filteau MJ; Baruch P; Lapierre YD; Bakish D; Blanchard A
    Int Clin Psychopharmacol; 1995 Mar; 10(1):51-4. PubMed ID: 7622805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer.
    Gothelf D; Rubinstein M; Shemesh E; Miller O; Farbstein I; Klein A; Weizman A; Apter A; Yaniv I
    J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1258-62. PubMed ID: 16292117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients.
    Katoh Y; Uchida S; Kawai M; Takei N; Mori N; Kawakami J; Kagawa Y; Yamada S; Namiki N; Hashimoto H
    Biol Pharm Bull; 2010; 33(12):1999-2002. PubMed ID: 21139240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Leckman JF; Holzer JC; Barr LC; McCance-Katz E; Heninger GR; Price LH
    Am J Psychiatry; 1993 Apr; 150(4):647-9. PubMed ID: 8465885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Velaxin (venlafaxine) in the treatment of anxious depression].
    Il'ina NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):24-8. PubMed ID: 18427537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Selective serotonin and noradrenaline reuptake inhibitors: a step forward in the treatment of depression?].
    Möller HJ; Bauer M; Fritze J; Haen E; Laux G; Müller WE; Rüther E
    MMW Fortschr Med; 2005 Jan; 147(3):43-5. PubMed ID: 15727113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Depression after age 50. Clinical case].
    Frémont P
    Encephale; 2000 Nov; 26 Spec No 5():61-2. PubMed ID: 11217527
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.